The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make inexpensive versions of Merck’s COVID-19 pill molnupiravir, according to a report.